


Syk-IN-6

Cat. No.:	HY-151634
CAS No.:	3018859-95-2
Molecular Formula:	C ₂₁ H ₂₂ N ₆ O ₂
Molecular Weight:	390.44
Target:	Syk; STAT; ERK
Pathway:	Protein Tyrosine Kinase/RTK; JAK/STAT Signaling; Stem Cell/Wnt; MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML) [1].											
IC₅₀ & Target	ERK2	ERK1	STAT3	STAT5								
In Vitro	<p>Syk-IN-6 (WC36) specifically and potently suppresses oncogenic activities of Syk in AML cell lines and patient-derived AML cells^[1].</p> <p>Syk-IN-6 (5 μM; 16 h) inhibits FcγRI-specific antibody (IgG2)-stimulated phosphorylation of Syk, STAT3/STAT5 and ERK1/2 in naive MV4-11 cells rather not entospletinib-resistant/Syk-deficient MV4-11 cells^[1].</p> <p>Syk-IN-6 (0.01 μM-100 μM; 16 h) inhibits the proliferation of MV4-11 cells, HL-60 and patient-derived AML cells by SykSH2 dose-dependently^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Raji B cell, HL-60 cell, naive and entospletinib-resistant MV4-11 cells</td> </tr> <tr> <td>Concentration:</td> <td>5 μM, 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>16 hours</td> </tr> <tr> <td>Result:</td> <td> Suppressed the phosphorylation and activation of Syk, ERK1/2 and STAT3/5 in entospletinib-resistant MV4-11 cells. Was potent against phosphorylation of ERK1/2 and STAT3 in HL-60 cells. Inhibited phosphorylation of Syk, ERK1/2 and STAT3/5 in AML cells from four patients refractory or relapsed following standard AML therapies. </td> </tr> </table>				Cell Line:	Raji B cell, HL-60 cell, naive and entospletinib-resistant MV4-11 cells	Concentration:	5 μM, 10 μM	Incubation Time:	16 hours	Result:	Suppressed the phosphorylation and activation of Syk, ERK1/2 and STAT3/5 in entospletinib-resistant MV4-11 cells. Was potent against phosphorylation of ERK1/2 and STAT3 in HL-60 cells. Inhibited phosphorylation of Syk, ERK1/2 and STAT3/5 in AML cells from four patients refractory or relapsed following standard AML therapies.
Cell Line:	Raji B cell, HL-60 cell, naive and entospletinib-resistant MV4-11 cells											
Concentration:	5 μM, 10 μM											
Incubation Time:	16 hours											
Result:	Suppressed the phosphorylation and activation of Syk, ERK1/2 and STAT3/5 in entospletinib-resistant MV4-11 cells. Was potent against phosphorylation of ERK1/2 and STAT3 in HL-60 cells. Inhibited phosphorylation of Syk, ERK1/2 and STAT3/5 in AML cells from four patients refractory or relapsed following standard AML therapies.											

REFERENCES

[1]. Singaram I, et al. Targeting lipid-protein interaction to treat Syk-mediated acute myeloid leukemia. Nat Chem Biol. 2022 Oct 13.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA